Pattern is a biotechnology company that uses single-cell microbiology to decode metabolic patterns of individual bacterial cells for rapid identification and antibiotic susceptibility testing (ID/AST) results.

Pattern

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. 

Each year, drug-resistant bacterial infections claim more than a million lives globally  and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. 

The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information.

The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

CARB-X

Omnimed Capital

Omninet Capital

Illumina Ventures

Daleshaw

Antimicrobial resistance

Pattern Bioscience

Thanks for the wonderful meeting, SWACM - Southwestern Association of Clinical Microbiology!  Congratulations to Melanie Yarbrough Meghan Wallace Megan Porter Kelly Alvarado for taking the prize for best poster.  Big thanks to everyone who stopped by our Pattern Bioscience booth.

Day 2 of our exhibition at ASM Microbe is underway, and we’re energized by the connections from Day 1. 

Want to learn more about our award-winning single-cell microbiology testing platform? Drop by booth #825 for a live demo and chat with our team.

Interested in our cutting-edge single-cell microbiology technology? Join Carey-Ann Burnham this Friday at 5:15pm at ASM Microbe for a spotlight discussion on our award-winning innovation.

Get ready to explore the future of microbiology with us at ASM Microbe this week in Atlanta. Catch us at one of our presentations or in booth #825 to see a demo of our single-cell microbiology system.

Join us at ASM Microbe 2024 to explore the future of microbiology. Discover our single-cell microbiology technology—an award-winning innovation poised to enable same-day, precise antibiotic treatment.
 
See you soon, Atlanta!

Meet the Forty Acres Founders Pitch Competition Judges Panel! 🚀💡

NICK ARAB - Co-Founder & CEO of Pattern Bioscience

Nick is the co-founder and CEO of Pattern Bioscience, an Austin-based med-tech startup developing a single-cell microbiology platform to solve antibiotic resistance. Under his guidance, Pattern has raised $68 million, including almost $50 million over multiple equity financings. Nick has over 15 years of experience developing FDA-cleared diagnostic products and technologies. Before founding Pattern in 2016, Nick was at Luminex for 10 years, most recently serving as Senior Director of the company’s Advanced Technology Group. He has innovated across several technical disciplines, twice winning Luminex’s “Top Inventor” award, and has been granted 39 patents with 37 patents pending. Nick obtained his B.S. in Electrical Engineering at UT Austin.

Come see what questions Nick has for the founders at the Forty Acres Founders Pitch Competition Finals on April 18th! RSVP today: https://bit.ly/49YV7Pq 

#FortyAcresFounders #StartupsStartHere #PitchCompetition

Pattern Bioscience, the winner of the 2023 Disruptive Technology Award, combines AI and novel microfluidics for single-cell microbiology. https://ow.ly/6VuK50QhoHh

Looking for an overview on how we’re tackling antibiotic resistance with our award-winning single-cell microbiology technology? The Association for Diagnostics & Laboratory Medicine has you covered with their recent article, featuring some insightful excerpts from Carey-Ann Burnham.

Antibiotic resistance is fueled in part by the days-long wait for culture-based tests. During this waiting period, providers often use broad-spectrum antibiotics to avoid treatment failure, inadvertently promoting overuse and misuse of antibiotics. 

Our solution? Provide same-day phenotypic antibiotic susceptibility results that guide healthcare providers in choosing targeted antibiotics quickly and confidently. 

#WAAW23 #AMR

There’s currently no rapid diagnostic test for #Pneumonia that provides same-day phenotypic antibiotic susceptibility results.  
 
We aim to address this unmet need to help ensure that patients receive the most targeted antibiotic treatment in a timely manner.  
 
#WorldPneumoniaDay

PATT

BIO:PATTERN

Pattern